[{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"STRO-002","moa":"Folate receptor alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sutro Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sutro Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Public Offering","leadProduct":"STRO-001","moa":"CD74","graph1":"Oncology","graph2":"Phase I","graph3":"Sutro Biopharma","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Sutro Biopharma \/ Cowen","highestDevelopmentStatusID":"6","companyTruncated":"Sutro Biopharma \/ Cowen"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Baillie Gifford","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Public Offering","leadProduct":"STRO-001","moa":"CD74","graph1":"Oncology","graph2":"Phase I","graph3":"Sutro Biopharma","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Sutro Biopharma \/ Baillie Gifford","highestDevelopmentStatusID":"6","companyTruncated":"Sutro Biopharma \/ Baillie Gifford"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"STRO-002","moa":"Folate receptor alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sutro Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sutro Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"STRO-002","moa":"Folate receptor alpha","graph1":"Oncology","graph2":"Preclinical","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sutro Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sutro Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"STRO-001","moa":"CD74","graph1":"Oncology","graph2":"Phase I","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sutro Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sutro Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"M1231","moa":"MUC1-EGFR","graph1":"Oncology","graph2":"Phase I","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Sutro Biopharma \/ Merck KGaA","highestDevelopmentStatusID":"6","companyTruncated":"Sutro Biopharma \/ Merck KGaA"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"STRO-002","moa":"Folate receptor alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sutro Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sutro Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"STRO-002","moa":"Folate receptor alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sutro Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sutro Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"STRO-002","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Sutro Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sutro Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Public Offering","leadProduct":"STRO-001","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sutro Biopharma","amount2":0.13,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.13,"dosageForm":"Intravenous Infusion","sponsorNew":"Sutro Biopharma \/ Cowen","highestDevelopmentStatusID":"6","companyTruncated":"Sutro Biopharma \/ Cowen"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"STRO-002","moa":"Folate receptor alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sutro Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sutro Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Cytokine derivative therapeutics","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sutro Biopharma","amount2":0.02,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"","sponsorNew":"Sutro Biopharma \/ Merck","highestDevelopmentStatusID":"5","companyTruncated":"Sutro Biopharma \/ Merck"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"M1231","moa":"MUC1-EGFR","graph1":"Oncology","graph2":"Phase I","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Sutro Biopharma \/ Merck KGaA","highestDevelopmentStatusID":"6","companyTruncated":"Sutro Biopharma \/ Merck KGaA"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"BioNova Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"STRO-001","moa":"CD74","graph1":"Oncology","graph2":"Phase I","graph3":"Sutro Biopharma","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.20000000000000001,"dosageForm":"Intravenous","sponsorNew":"Sutro Biopharma \/ BioNova Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Sutro Biopharma \/ BioNova Pharmaceuticals"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Tianjin Tasly Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"STRO-002","moa":"Folate receptor alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Sutro Biopharma","amount2":0.39000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.39000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Sutro Biopharma \/ Tasly Biopharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Sutro Biopharma \/ Tasly Biopharmaceuticals"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Immunostimulatory Antibody-drug Conjugate","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Sutro Biopharma","amount2":0.51000000000000001,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.51000000000000001,"dosageForm":"","sponsorNew":"Sutro Biopharma \/ Astellas Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Sutro Biopharma \/ Astellas Pharma"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"MK-1484","moa":"IL-2","graph1":"Oncology","graph2":"Phase I","graph3":"Sutro Biopharma","amount2":1.6599999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":1.6599999999999999,"dosageForm":"Injectable\/Injection","sponsorNew":"Sutro Biopharma \/ Merck","highestDevelopmentStatusID":"6","companyTruncated":"Sutro Biopharma \/ Merck"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"STRO-002","moa":"Folate receptor alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sutro Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sutro Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Vaxcyte","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"24-valent Pneumococcal Conjugate Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sutro Biopharma","amount2":0.16,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.16,"dosageForm":"Injectable\/Injection","sponsorNew":"Sutro Biopharma \/ Vaxcyte","highestDevelopmentStatusID":"8","companyTruncated":"Sutro Biopharma \/ Vaxcyte"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"STRO-002","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sutro Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sutro Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Luveltamab Tazevibulin","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sutro Biopharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Sutro Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Blackstone Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Collaboration","leadProduct":"24-valent Pneumococcal Conjugate Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sutro Biopharma","amount2":0.39000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.39000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Sutro Biopharma \/ Blackstone Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Sutro Biopharma \/ Blackstone Life Sciences"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Vaxcyte","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Agreement","leadProduct":"24-valent Pneumococcal Conjugate Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sutro Biopharma","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.16,"dosageForm":"Injection","sponsorNew":"Sutro Biopharma \/ Vaxcyte","highestDevelopmentStatusID":"8","companyTruncated":"Sutro Biopharma \/ Vaxcyte"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Public Offering","leadProduct":"Luveltamab Tazevibulin","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Sutro Biopharma","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Injection","sponsorNew":"Sutro Biopharma \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Sutro Biopharma \/ BofA Securities"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Ipsen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Licensing Agreement","leadProduct":"STRO-003","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Sutro Biopharma \/ Ipsen","highestDevelopmentStatusID":"4","companyTruncated":"Sutro Biopharma \/ Ipsen"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Luveltamab Tazevibulin","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sutro Biopharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Sutro Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"VGXI","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Partnership","leadProduct":"Luveltamab Tazevibulin","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sutro Biopharma \/ Sutro Biopharma","highestDevelopmentStatusID":"9","companyTruncated":"Sutro Biopharma \/ Sutro Biopharma"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Luveltamab Tazevibulin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Sutro Biopharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Sutro Biopharma \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals by Sutro Biopharma
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
